<DOC>
	<DOCNO>NCT01789320</DOCNO>
	<brief_summary>This study design determine safety tolerability single microinjection triamcinolone acetonide ( TRIESENCE® ) suprachoroidal space ( SCS ) patient non-infectious uveitis .</brief_summary>
	<brief_title>Safety Study Suprachoroidal Triamcinolone Acetonide Via Microneedle Treat Uveitis</brief_title>
	<detailed_description>This Phase 1/2 , open-label study design evaluate safety , tolerability procedure microneedle injection triamcinolone acetonide ( TA ) SCS . The subject enrol study choose subject non-infectious intermediate , posterior pan-uveitis . The injection administer single eye via Clearside Biomedical proprietary microneedle SCS . The dose TA inject 4 mg currently approve TRIESENCE® ( triamcinolone acetonide injectable suspension 40 mg/mL ) . The study design include 10 clinic visit 27 week . Subjects follow 26 week follow treatment TRIESENCE® .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Uveitis , Posterior</mesh_term>
	<mesh_term>Uveitis , Intermediate</mesh_term>
	<mesh_term>Pars Planitis</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>diagnosis noninfectious intermediate , posterior panuveitis ocular trauma within past 6 month study eye injection intraocular corticosteroid steroid implant Ozurdex® implant 6 month prior study treatment , prior use Retisert™ study eye uncontrolled systemic disease would preclude participation study put subject risk due study treatment procedure know HIV infection immunodeficiency disease corticosteroid therapy would contraindicate monocular ocular hypertension history intraocular surgery study eye presence anterior staphyloma study eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>uveitis</keyword>
	<keyword>intermediate uveitis</keyword>
	<keyword>posterior uveitis</keyword>
	<keyword>panuveitis</keyword>
	<keyword>noninfectious uveitis</keyword>
	<keyword>microneedle</keyword>
	<keyword>suprachoroidal space</keyword>
	<keyword>SCS</keyword>
	<keyword>inflammation</keyword>
	<keyword>ocular inflammatory condition</keyword>
	<keyword>triamcinolone acetonide</keyword>
	<keyword>TA</keyword>
	<keyword>Triesence</keyword>
	<keyword>injection</keyword>
	<keyword>IVT</keyword>
	<keyword>intravitreal</keyword>
	<keyword>corticosteroid</keyword>
	<keyword>sympathetic ophthalmia</keyword>
	<keyword>temporal arteritis</keyword>
	<keyword>vitreous haze</keyword>
</DOC>